1. Home
  2. GME vs CINGW Comparison

GME vs CINGW Comparison

Compare GME & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GME
  • CINGW
  • Stock Information
  • Founded
  • GME 1996
  • CINGW N/A
  • Country
  • GME United States
  • CINGW United States
  • Employees
  • GME N/A
  • CINGW 13
  • Industry
  • GME Electronics Distribution
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • GME Consumer Discretionary
  • CINGW Health Care
  • Exchange
  • GME Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • GME N/A
  • CINGW N/A
  • IPO Year
  • GME 2002
  • CINGW 2021
  • Fundamental
  • Price
  • GME $27.00
  • CINGW $0.05
  • Analyst Decision
  • GME Sell
  • CINGW
  • Analyst Count
  • GME 1
  • CINGW 0
  • Target Price
  • GME $10.00
  • CINGW N/A
  • AVG Volume (30 Days)
  • GME 5.8M
  • CINGW N/A
  • Earning Date
  • GME 03-25-2025
  • CINGW N/A
  • Dividend Yield
  • GME N/A
  • CINGW N/A
  • EPS Growth
  • GME N/A
  • CINGW N/A
  • EPS
  • GME 0.17
  • CINGW N/A
  • Revenue
  • GME $4,334,000,000.00
  • CINGW N/A
  • Revenue This Year
  • GME N/A
  • CINGW N/A
  • Revenue Next Year
  • GME N/A
  • CINGW N/A
  • P/E Ratio
  • GME $159.05
  • CINGW N/A
  • Revenue Growth
  • GME N/A
  • CINGW N/A
  • 52 Week Low
  • GME $9.95
  • CINGW N/A
  • 52 Week High
  • GME $64.83
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • GME 48.38
  • CINGW N/A
  • Support Level
  • GME $25.60
  • CINGW N/A
  • Resistance Level
  • GME $27.76
  • CINGW N/A
  • Average True Range (ATR)
  • GME 0.99
  • CINGW 0.00
  • MACD
  • GME 0.11
  • CINGW 0.00
  • Stochastic Oscillator
  • GME 55.63
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: